Establishment Labs Announces Participation in Two Upcoming Investment Conferences

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.

Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Interim Chief Financial Officer and Head of Strategy and Investor Relations, will participate in the 2021 Jefferies London Healthcare Conference which is being held November 16-19, 2021. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak in-person to conference attendees at 12:20 pm GMT on Tuesday, November 16, 2021.

Mr. Chacón-Quirós and Mr. Denhoy will also participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum being held on November 18, 2021. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak via webcast to conference attendees at 2:00 pm ET on Thursday, November 18, 2021.

Live webcasts of the presentations will be available to all interested parties on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants^® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 1.8 million Motiva Implants^® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora^® tissue expander and Motiva MIA^®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant^® and began a clinical trial to support regulatory approval in the United States. Motiva Implants^® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005284/en/